HealthEx London 2015

HealthEx London is where CEOs, CFOs and Chairmen of listed life science and healthcare companies debate the strategies for investor engagement and education; problem solve fundraising and capital challenges and come together to share ideas on how to promote and cultivate a strong and vibrant environment for life science investment.

HealthEx London is a highly exclusive gathering of the finest minds and leaders of life science and healthcare listed companies in the UK. It offers a seedbed of ideas that will fundamentally transform the sector in the UK, and a seat at the discussion table is one of the most highly coveted invitations a CEO, CFO and Chairman can receive.

• • Keynotes and special addresses from game changers and disruptors
• • 1.5hr sub-themed discussion groups on business critical issues
• • Formats to encourage bilateral discussions and meetings
• • Genuine peer-to-peer interactions and knowledge sharing
• • Cross-mentoring opportunities between IPO and pre-IPO Executives
• • Chatham House Rules

HealthEx London is an invite only, executive gathering for C-level executives from Main Market and LSE AIM listed companies. A select number of seats will also be made available for UK based executives from Euronext and NASDAQ listed companies.

The forum will also open up exclusive invitations to a limited number of pre-IPO CEOs, CFOs and their Chairmen. These invitations will be allocated based on a nomination process from existing participants.

The pre-IPO nomination allocation allows cross cultivation of knowledge between existing and soon to IPO executives.

The first forum of its kind was held in conjunction with Biotech and Money London on 3rd February 2015. The forum brought together CEOs and CFOs from Circassia, Horizon Discovery, Clinigen, Oxford Biomedica, Abzena, Tigenix, Oxford Pharmascience, Sareum, Verona Pharma, ReNeuron, Scancell Holdings, Ablynx, Epistem, Synairgen, Novogen and BioInvent International.

The forum provided the opportunity for high level discussion and debate on problems and opportunities facing publicly listed companies and their management teams.